A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE)

The purpose of this study is to investigate the efficacy of enzastaurin compared to placebo in preventing arterial events (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) leading to intervention or mortality attributable to an arterial event in patients with vEDS confirmed with pathogenic heterozygous COL3A1 gene mutations predicted to derive a mutant protein.

开始日期2025-01-01

申办/合作机构

Aytu Biopharma, Inc.

[+1]

CTR20210055 / Recruiting临床3期

在新诊断为胶质母细胞瘤并且全新生物标记物DGM1 阳性患者中评估Enzastaurin联合替莫唑胺同步放化疗加辅助化疗方案的随机双盲安慰剂对照III期临床试验

主要目的：在新诊断为胶质母细胞瘤的Denovo基因标记物1（DGM1）阳性患者中，与安慰剂对照，评估enzastaurin联合替莫唑胺同步放化疗加辅助化疗方案在患者总生存期（OS）方面的优效性。次要目的： 1. 在DGM1生物标记物阳性患者中比较治疗组间的无进展生存期（PFS）。 2. 在DGM1生物标记物阳性患者中比较治疗组间的客观缓解率（ORR）。 3. 进一步评估enzastaurin加入替莫唑胺同步放化疗加辅助化疗方案后的安全性特征。探索性目的： 1. 在DGM1生物标记物阴性患者中评估总生存期（OS）。 2. 确定色素尿的存在（尿液呈橙色/红色）是否与服用enzastaurin的患者生存期改善存在关联。 3. 分析尿液中是否存在enzastaurin和enzastaurin代谢产物（尿液药代动力学[PK]）。 4. 评估其它胚系或肿瘤生物标记物的存在是否与服用enzastaurin的患者的疗效改善存在关联。 5. 确定enzastaurin和enzastaurin代谢产物的浓度，以便纳入后续的群体PK分析中。

开始日期2021-07-13

申办/合作机构

Xcelience LLC

[+2]

NCT03776071 / Completed临床3期

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.

开始日期2020-12-16

申办/合作机构

Denovo Biopharma LLC

100 项与盐酸恩扎妥林相关的临床结果

登录后查看更多信息

100 项与盐酸恩扎妥林相关的转化医学

登录后查看更多信息

100 项与盐酸恩扎妥林相关的专利（医药）

登录后查看更多信息

253

项与盐酸恩扎妥林相关的文献（医药）

2023-11-01·Environmental Toxicology

LncRNA AP000487.1 regulates PRKCB DNA methylation‐mediated TLR4/MyD88/NF‐κB pathway in Nano NiO‐induced collagen formation in BEAS‐2B cells

Article

作者: Sun, Yingbiao ; Qin, Xin ; Zheng, Jinfa ; Li, Kun ; Wang, Jinyu ; Li, Sheng ; Chang, Xuhong

Abstract:

Nickel oxide nanoparticles (Nano NiO) have been shown to cause pulmonary fibrosis; But, the underlying epigenetic mechanisms remain poorly understood. In this study, we aimed to investigate the role of lncRNA AP000487.1 in regulating PRKCB DNA methylation and the Toll‐like receptor 4 (TLR4)/ Myeloid differentiation primary response 88 (MyD88)/ Nuclear factor kappa‐B (NF‐κB) pathway in Nano NiO‐induced collagen formation. We found that lncRNA AP000487.1 was able to bind to the promoter region of the PRKCB gene by Chromosomal RNA pull‐down experiments (Ch‐RNA pull‐down). Moreover, Nano NiO exposure led to down‐regulation of lncRNA AP000487.1 expression and PRKCB DNA methylation, resulting in up‐regulation of PRKCB expression, activation of the TLR4/MyD88/NF‐κB pathway, and increased collagen formation in BEAS‐2B cells. Conversely, overexpression of lncRNA AP000487.1 restored PRKCB expression, reduced its hypomethylation and attenuated TLR4/MyD88/NF‐κB pathway activation and collagen formation. Furthermore, treatment with the DNA methylation inhibitor, decitabine, alleviated Nano NiO‐induced PRKCB2 expression, TLR4/MyD88/NF‐κB pathway activation, and collagen formation. Additionally, using PRKCB2 overexpression plasmid, PRKCB2 siRNA, and PRKCB2 protein inhibitor LY317615 influenced NF‐κB pathway activity and collagen formation. Finally, TLR4 inhibitor (TAK‐242) restrained Nano NiO‐induced MyD88/NF‐κB pathway activation and excessive collagen formation. In summary, we demonstrated that the down‐regulated lncRNA AP000487.1 could cause PRKCB hypomethylation and increased expression, resulting in NF‐κB pathway activation and collagen formation in Nano NiO‐induced BEAS‐2B cells. This is the first study to reveal the role of lncRNA AP000487.1 in regulating collagen formation in Nano NiO‐exposed BEAS‐2B cells. Our study identified that lncRNA AP000487.1/PRKCB hypomethylation/NF‐κB pathway was a regulatory axis of BEAS‐2B cells collagen excessive formation. Our findings indicate that lncRNA AP000487.1 and PRKCB DNA methylation may function as biomarkers or potential targets in response to Nano NiO exposure.

2023-08-22·Pharmaceuticals (Basel, Switzerland)

Bisindolyl Maleimides and Indolylmaleimide Derivatives-A Review of Their Synthesis and Bioactivity.

Review

作者: Cooney, Louise N ; O'Shea, Kevin D ; Winfield, Hannah J ; Pierce, Larry T ; Cahill, Michael M ; McCarthy, Florence O

The evolution of bisindolyl maleimides and indolyl maleimide derivatives and their unique biological activities have stimulated great interest in medicinal chemistry programs. Bisindolylmaleimide (BIM)-type compounds arise from natural sources such as arcyriarubin and are biosynthetically related to indolocarbazoles. BIMs are commonly the immediate synthetic precursors of indolocarbazoles, lacking a central bond between the two aromatic units and making them more flexible and drug-like. Synthetic endeavours within this class of compounds are broad and have led to the development of both remarkably potent and selective protein kinase inhibitors. Clinical BIM examples include ruboxistaurin and enzastaurin, which are highly active inhibitors of protein kinase C-β. While BIMs are widely recognised as protein kinase inhibitors, other modes of activity have been reported, including the inhibition of calcium signalling and antimicrobial activity. Critically, structural differences can be used to exploit new bioactivity and therefore it is imperative to discover new chemical entities to address new targets. BIMs can be highly functionalised or chemically manipulated, which provides the opportunity to generate new derivatives with unique biological profiles. This review will collate new synthetic approaches to BIM-type compounds and their associated bioactivities with a focus on clinical applications.

2023-05-02·International journal of molecular sciences

Simultaneously Targeting Two Coupled Signalling Molecules in the Mesenchymal Stem Cell Support Efficiently Sensitises the Multiple Myeloma Cell Line H929 to Bortezomib.

Article

作者: Meyer-Herrera, J E ; Rojas-Zambrano, P M ; Ruiz-Aparicio, P F ; Vernot, J P

Several studies have shown that diverse components of the bone marrow (BM) microenvironment play a central role in the progression, pathophysiology, and drug resistance in multiple myeloma (MM). In particular, the dynamic interaction between BM mesenchymal stem cells (BM-MSC) and MM cells has shown great relevance. Here we showed that inhibiting both PKC and NF-κB signalling pathways in BM-MSC reduced cell survival in the MM cell line H929 and increased its susceptibility to the proteasome inhibitor bortezomib. PKC-mediated cell survival inhibition and bortezomib susceptibility induction were better performed by the chimeric peptide HKPS than by the classical enzastaurin inhibitor, probably due to its greatest ability to inhibit cell adhesion and its increased capability to counteract the NF-κB-related signalling molecules increased by the co-cultivation of BM-MSC with H929 cells. Thus, inhibiting two coupled signalling molecules in BM-MSC was more effective in blocking the supportive cues emerging from the mesenchymal stroma. Considering that H929 cells were also directly susceptible to PKC and NF-κB inhibition, we showed that treatment of co-cultures with the HKPS peptide and BAY11-7082, followed by bortezomib, increased H929 cell death. Therefore, targeting simultaneously connected signalling elements of BM-MSC responsible for MM cells support with compounds that also have anti-MM activity can be an improved treatment strategy.

项与盐酸恩扎妥林相关的新闻（医药）

2024-04-28

·研发客

用7年，验证一个抑郁症biomarker | DJS

// 索元生物历经7年，用其全基因组平台找到其在研产品DB104的生物标志物DGM4，且已证明了药物疗效。DB104的治疗群体是难治性抑郁症，其生物标志物DGM4在20%的难治性抑郁症患者中呈阳性。近期索元已经开启对外授权合作的步伐。在5月的2024年DJS创新合作峰会上，索元生物将现场路演。撰文 | 殷丹妮索元生物董事长罗文博士告诉研发客，公司正在和多家国际大药厂接洽合作事宜。这主要得益于DB104治疗难治性抑郁症（TRD）的关键性临床试验积极结果的公布。从2012年成立至今12年，索元终于在首个产品上证明了其精准医疗“基因组学+新药”的研发理念。综观索元的模式，乃是引入临床“失败”新药，利用大数据组学打造的全基因组平台发现生物标志物（biomarker），通过新发现的biomarker筛选患者并重新开展临床试验，验证药物疗效。DB104在2b期临床中证明了对TRD的疗效，也证明了索元模式“biomarker+新药”的可行性。索元生物董事长罗文罗文认为，如果DB104能成功上市，将是CNS领域第一个精准医疗的突破，类似于当年易瑞沙找到EGFR突变对于肺癌的意义。同时他表示，随着DB104的成功，将有计划重启IPO之路。2017年，索元生物从BMS收购DB104时，研发客就采访过罗文（拓展阅读索元获AMRI/BMS抗抑郁药全球授权，新模式见真章）。7年过后，索元不仅找到DB104的生物标志物DGM4，且已证明了药物疗效。索元生物首席财务官陈纪正女士将在2024DJS代表公司路演。欢迎参与投票“谁是您最喜爱的路演公司”，投票时间从即日起至5月15日16:00，活动详情见本期次条。或将申请有条件上市研发客：请您介绍一下DB104治疗难治性抑郁症的具体研究情况、疗效如何？罗文：这项关键性国际多中心临床研究ENLIGHTEN，共纳入197例患者，治疗6周后，在基因生物标志物DGM4阳性TRD患者中达到主要临床终点和所有次要终点。其中在主要终点蒙哥马利-阿斯伯格抑郁量表（MADRS）总分相对于基线的变化方面，DB104用药组量表打分相比安慰剂组要低4.4分（p值0.0056）, 将近40%的改善。单从MADRS评分看，DB104疗效与已获批治疗TRD的Spravato疗效相当。Spravato在56mg或84mg剂量的MADRS总分未超过4分。并且DB104在安全性和使用便利性层面也具备优势。Spravato为鼻喷制剂，DB104是每天口服一次的片剂。DB104在2017年被收购前，BMS已开展了11项1期、3项2b期大型临床试验，在上千例患者中验证了产品的安全性和耐受性。而Spravato改良于麻醉剂氯胺酮，上市后因安全性问题和滥用风险被FDA加以黑框警告，只能在医生监督下使用，给药两小时内须由专业人员陪护，一定程度上限制了其临床应用。研发客：DB104将来上市将有多大的市场空间？销售峰值将达多少？罗文：DB104的治疗群体是难治性抑郁症。根据人民日报发布《2022年国民抑郁症蓝皮书》，中国患抑郁症人数超过9500万，其中难治性抑郁症患者占这近1亿例中的约三分之一。且DB104的生物标志物DGM4在20%的TRD患者中呈阳性。20%的比例在生物标志物中已属于较高比例，一些肿瘤突变基因NTRK1、ROS1、RET等只有1%~2%比例，但不妨碍各大药厂投入重金研发。从竞争对手看，Spravato于2019年在美国上市后销量持续上涨，2024年第一季度销售额达2.25亿美金，同比增长72%，成为年销售额超过十亿美金的“重磅炸弹”应该没有悬念。DB104从药物依从性、安全性各方面相较Spravato都有优势。我们预测DB104上市后全球的峰值销售可能会接近20亿美金。研发客：索元生物对DB104进一步的规划是什么？罗文：产品的注册申请程序正在按部就班的进行中。DB104在2b期临床试验获得积极数据，我认为有可能尝试将其作为关键性临床（pivotal trial）结果向药监部门申请有条件上市的批准。此外，我们也正在和一些国际大厂沟通合作事宜。近年国内药企授权出海浪潮正热，一些创新药甚至在临床前就被授权。而且大药厂有强势回归CNS趋势，仅2023年底就有两笔大额收购交易，即BMS以140亿美金收购Karuna、艾伯维87亿美金收购Cerevel。类似于DB104的first-in-class新药，也高度符合MNC的需求，尤其是DB104已获得2b期积极结果。从索元公司本身看，自2012成立至今一直坚持精准医疗，需要有一个突破口证明我们的研发策略是正确的。如今DB104获得重大突破，索元短期将集中所有资源用于这款产品开发。容易检测到的biomarker研发客：可否请您以DB104为例，解释一下索元筛选biomarker的过程？罗文：我们收集了BMS针对DB104开展的两项2b期临床试验，在试验受试者的全血样本中提取DNA，对其中上百例样本进行了全基因组扫描，从上百万个位点中通过大数据分析、人工智能等多种计算工具，历经两年时间，最终发现了一个全新的生物标志物并将其命名为Denovo Genomic Marker4（DGM4）。同时，为验证DGM4是预测疗效的药物基因组生物标志物，而非疾病预后生物标志物。我们在对照组受试者中开展相同的生物标志物分析，结果表明，DGM4是可以预测疗效的生物标志物。索元的生物标志物发现平台研发客：索元生物标志物发现平台的特点和难点是什么？罗文：biomarker的寻找已历经3代，第一代的典型是易瑞沙，药物靶点就是biomarker；第二代的代表是结肠癌治疗药物Erbitux，靶点是EGFR，biomarker则是KRAS。KRAS在EGFR信号传导通路的下游，寻找起来相对复杂。一代和二代生物标志物都是从已有的科学文献推测，属于知识导向。索元模式是第三代，不再局限于已知的生物信息传导通路，而是以数据导向的反向式检索，在全人类基因组中扫描。这也应对了索元生物的英文名称Denovo，完全从头发现，是从0到1的过程。这是索元模式的核心也是难点。人类基因组共有30亿个碱基对，从30亿位点中找出一两个跟药效相关的biomarker，无异于大海捞针。所以，尽管前期我们收购药物时进行了精挑细选，也不能保证每个项目都能找到biomarker。例如DB103，自收购至今6年多时间仍未找到其生物标志物，但我们仍未放弃。索元管线的8款产品（见下图）中，有DB102、DB104和DB107发现了biomarker，分别是DGM1、DGM4和DGM7。而一旦找到了biomarker，其应用就非常容易，普及率很高。以肿瘤生物标志物来做对比。通常抗肿瘤药的伴随诊断所针对的肿瘤突变基因，必须从肿瘤组织提取进行活检。而索元的biomarker是由SNP（单核苷酸多态性）组成的生物标志物，胚系SNP来自父母遗传，存在于全身各个细胞中，因此通过血液、甚至唾液就能检测，不需要获取病灶组织的样本。这种核酸检测简易快捷，方便临床患者，可以做到无创检测。总结起来，找biomarker特别困难，但检测非常容易，这也是索元模式的一大特色。我们在DB104临床入组预筛时就使用过该方法，效率非常高。上市之路可能重启研发客：索元生物的研发理念需要哪些核心技术的融合？罗文：索元生物的研发模式，是一项跨学科的系统工程，将大数据基因组学应用于创新药研发，汇集了大数据、基因组学、分子生物学、临床各类学科人才。而我本身的职业生涯也跨越了多个领域。本科是临床医学，研究生是分子生物学。工作后在蛋白激酶研发前沿公司Sugen（后被辉瑞收购），及Ligand Pharmaceutical从事新药研发。在人类基因组完成的2000年，加入当时最大的基因组学公司Incyte Genomics，对于基因组大数据的价值有切身感受。跨学科的职业经历，也让我认定要将基因组学应用于创新药的研发。研发客：索元生物在关注哪些前沿技术，开展哪些技术合作？罗文：索元生物本身就是商业模式及技术平台超前的研发驱动公司，自然对各类创新技术充满兴趣，也正在和全球最前沿的公司和科研院所合作，不断提升自身研发水平。如，与Nurosene合作，利用AI技术NetraPlacebo帮助解决CNS临床试验中的安慰剂效应，提升试验成功率。索元生物还与哈佛大学、清华大学的脑电波专家合作过。目前CNS临床终点大多是量表打分，例如抑郁症的汉密尔顿抑郁量表、蒙哥马利抑郁量表，而量表打分具有主观性，脑电波是客观的定量指标。不过这些都属于探索性实践合作，真正用于临床还需要获得监管部门的认可，在此之前的临床终点还是必须依据现有国际金标准。研发客：2021年撤回科创板IPO申请后，索元还考虑上市吗？罗文：2021年中国药品市场热点是biosimilar和me-too药物，科创板、港股上市的大部分是这类药企。索元模式至今在全球范围内都没有同类企业，当时更是没有。公司独特的商业模式没有得到验证，这都是挑战。而如今DB104临床成功，核心技术DGM生物标志物发现平台得到验证，我认为公司的上市之路已被打开。同时，DB104对外授权合作也在同步展开，产生的超额收益使公司能够提前进入投资丰收期。而且药监部门一直在支持精准医疗开发。2021年底CDE发布了《生物标志物在抗肿瘤药物临床研发中应用的技术指导原则》，而后在ADC、PD-1/L1、基因治疗等各类指南中都提及生物标志物的重要性。编辑 | 姚嘉yao.jia@PharmaDJ.com 总第2097期访问研发客网站可浏览更多文章www.PharmaDJ.com

并购IPO临床2期申请上市临床1期

2023-11-21

·PRNewswire

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting. "The 2023 SNO Annual Meeting was another successful event with the latest advances in clinical trials, diagnosis and treatment of pediatric and adult patients with CNS malignancies," stated Dr. John Friend, CEO Kazia. "We are highly encouraged with the preliminary overall survival data from the PNOC022 clinical study that we believe will provide an alternative to the current therapies considered as standard of care." Key paxalisib highlights from the meeting: Friday, November 17th Combining ONC201 and paxalisib for the treatment of diffuse midline glioma (DMG); the preclinical results underpinning the international Phase II clinical trial (NCT05009992). Presenter: Evangeline R. Jackson; University of Newcastle, NSW, Australia The mechanism of action of both paxalisib and ONC201 were reviewed as well as the synergistic effects of their combination in DMG preclinical models Specifically, the authors observed how ONC201 over activates the PI3K-AKT pathway, which is the target pathway for paxalisib Consistent and statistically significant improvements were observed with the combination of paxalisb and ONC201 in DMG preclinical mouse models Two patient case studies were discussed; each receiving the combination of paxalisib and ONC201 through compassionate access 16-year old female with advanced and relapsed diffuse intrinsic pontine glioma (DIPG) who demonstrated significant neurological improvements as well as rapid tumour regression after receiving the combination Six-year old female with DIPG who received the combination of paxalisib and ONC201 after upfront radiation therapy. Tumor regression has been maintained for more than two years on paxalisib and ONC201 Exploiting the genetic dependency on PI3K/mTOR signaling for the treatment of H3-altered Diffuse Midline Glioma Presenter: Ryan Duchatel, PhD; University of Newcastle, NSW, Australia PI3K pathway activation is observed in >80% of all DMGs and was shown to be required for DMG cell growth The authors stated that the success of a monotherapy in DMG is highly unlikely; therefore they explored several combinations [of other therapies] with paxalisib with the aim of optimizing tolerability and efficacy of such combinations in preclinical mouse studies Adding metformin to paxalisib was observed to improve hyperglycemia (elevated blood glucose) as well as extend the overall survival rate The combination of paxalisib and enzastaurin (PKC inhibitor) was observed to further extend the overall survival when combined to radiation treatment Authors concluded the triple combination of paxalisib, enzastaurin and metformin warranted further investigation in clinical trials Phase I study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations: pilot analysis of circulating tumor DNA for patient eligibility confirmation and post-treatment response Presenter: Brandon Imber, MD, Memorial Sloan Kettering Cancer Center, NYC, USA This is a multi-institutional, Phase I trial of concurrent paxalisib and radiation therapy in patients with brain metastases with documented PI3K pathway mutations Study has expanded after data from the initial stage identified the maximal tolerated dose (45mg once daily) along with observed signals of clinical activity (100% response rate) The authors observed that plasma circulating tumor DNA (ctDNA) was able to accurately confirm the tumor's genetic mutations at baseline and can potentially be used as a biomarker to assess patient treatment response The authors presented a representative case from the ongoing Phase I study: 70-year-old woman with metastatic breast cancer with tumor harboring PIK3CA mutation received radiation therapy in combination with paxalisib for brain metastases Her baseline plasma ctDNA test before starting treatment detected the same PIK3CA mutation as her tumor MRI scan three months after treatment demonstrated radiographic response. In addition, a 99% reduction in the amount of ctDNA with PIK3CA mutation compared to baseline was detected, indicating ctDNA can potentially be used as an accurate method to monitor response after radiation therapy in combination with paxalisib This is the first time in this patient population to demonstrate a link between MRI findings and a blood-based measure of tumor burden (ctDNA) Sunday, November 19 PNOC022: a combination therapy trial using an adaptive platform design for patients with diffuse midline gliomas (DMGs) at initial diagnosis, post-radiation therapy and at time of therapy Presenter: Sabine Mueller, MD, UCSF, San Francisco, USA 30 sites open to enrollment in North America, Europe and Australia Total enrollment to date: 137 patients Cohort 1 (newly diagnosed) = 37 patients Cohort 2 (post radiation therapy) = 69 patients (one patient was replaced due to physician preference) Cohort 3 (at the time of recurrence) = 31 patients Cohort 2 preliminary analyses (median follow-up time was approximately 9 months) Median Overall Survival rate was 16.5 months Median Progression Free Survival (PFS) was 9.9 months (central review is ongoing) Analysis of preliminary data from all cohorts is still ongoing and the protocol is subject to amendment to refine dosing with the aim of improving tolerability and efficacy at which time the enrollment of new patients will start Additional data includes ctDNA, microbiome and quality of life measures This announcement was authorized for release by Dr. John Friend, CEO. About Kazia Therapeutics Limited Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, DMGs, and primary CNS lymphoma, with several of these having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US Food and Drug Administration (US FDA) in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. A Phase I study in advanced solid tumors commenced recruitment in November 2021. For more information, please visit or follow us on Twitter @KaziaTx. Forward-Looking Statements This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia's clinical and preclinical trials, and Kazia's strategy and plans with respect to its programs, including paxalisib and EVT801, as well as any potential future indications and timing for the release of interim or final data for such programs. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the United States Securities and Exchange Commission (SEC), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. SOURCE Kazia Therapeutics Limited

临床结果临床1期快速通道孤儿药临床2期

2023-05-01

·PRNewswire

Significant Positive Shift in the Glioma Market with 13% CAGR During the Study Period (2019-2032) Expected by Analysts at DelveInsight

The dynamics of the glioma market are anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players, such as Bayer, VBL Therapeutics, Candel Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, and others LAS VEGAS, May 1, 2023 /PRNewswire/ -- DelveInsight's Glioma Market Insights report includes a comprehensive understanding of current treatment practices, glioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Glioma Market Report As per DelveInsight analysis, the glioma market size in the 7MM was approximately USD 1 billion in 2022. According to the assessment done by DelveInsight, the estimated total incident glioma cases in the 7MM were approximately 47K in 2022. Leading glioma companies such as Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, and others are developing novel glioma drugs that can be available in the glioma market in the coming years. The promising glioma therapies in the pipeline include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12 (Olaptesed Pegol), Tovorafenib (DAY101), Vorasidenib (AG-881), Eflornithine, TVI-Brain-1, AB-218, BGB-290, Mirdametinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, PEMAZYRE (Pemigatinib), VERZENIO (abemaciclib) , and others. In December 2022, Chimerix announced the successful launch of the ONC201 Phase III ACTION study in patients with H3 K27M-mutant glioma. In June 2022, Day One Biopharmaceuticals announced positive initial data from its pivotal Phase II (FIREFLY-1) study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG). Discover which therapies are expected to grab the major glioma market share @ Glioma Market Report Glioma Overview Glioma is the most common kind of glial cell tumor in the central nervous system (CNS). Gliomas are infiltrative tumors that affect the brain tissue surrounding them. Glioblastoma is the most hazardous type of brain tumor, whereas pilocytic astrocytomas are the least dangerous. Previously, diffuse gliomas were classified into subgroups and grades depending on histopathologies, such as diffuse astrocytomas, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. The specific etiology of glioma, like other primary brain tumors, remains unknown. However, certain variables may increase the risk of getting a brain tumor. Glioma symptoms vary depending on tumor type, size, location, and growth rate. Some common glioma symptoms include headache, nausea or vomiting, memory loss, urine incontinence, speech problems, and others. A medical history and a physical examination are used for glioma diagnosis. Glioma Epidemiology Segmentation DelveInsight estimates that there were approximately 47K incident cases of glioma in the 7MM in 2022. As per our analysis, the United States contributed to the largest incident population of glioma, acquiring ~40% of the 7MM in 2022. The glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total glioma incident cases Glioma grade-specific cases Glioma age-specific cases Glioma type-specific cases Download the report to understand which factors are driving glioma epidemiology trends @ Glioma Epidemiological Insights Glioma Treatment Market Glioma treatment is based on the type of glioma, its size and location, and the patient's unique characteristics. Chemotherapy and radiation therapy will be administered after surgery, particularly in individuals when the tumor cannot be removed entirely because it has invaded critical parts of the brain or is inaccessible. The typical glioma treatment protocol comprises surgery, chemotherapy, and radiation. Chemotherapy may include carmustine (BCNU), lomustine (CCNU), or gleostine (generic), cisplatin, carboplatin, etoposide, and irinotecan in case of low-grade glioma whereas temozolomide (TEMODAR) is the standard chemotherapy used in case of high-grade glioma majorly, Gliadel wafer implants (biodegradable discs injected with BCNU) are usually given as adjunctive treatment after surgery, although usage of Gliadel wafers remains a point of controversy due to its questionable survival benefits. Avastin (Genentech) and Temodar/Temodal (Merck), among others, are approved medications for HGG. However, due to patent expiration, the generic version of Temodar and biosimilars of Avastin are available on the glioma market. As generics and biosimilars are more cost-effective for patients than new medicines, intense competition exists among them. Furthermore, due to a lack of knowledge concerning bevacizumab's overall survival benefit, it is not recommended in unselected patients with newly diagnosed GBM. Currently, only one medication for LGG is approved, Tafinlar (dabrafenib) plus Mekinist (trametinib). Moreover, the current therapeutic market lacks a viable method for curing glioblastoma; therefore, the survival rate of people diagnosed with glioma remains poor. Glioma is incurable, and treatment choices are limited. Furthermore, the tumor has a high recurrence rate and a poor patient prognosis. In addition, there is currently no approved therapy for the unmethylated MGMT patient pool. To know more about glioma treatment guidelines, visit @ Glioma Management Glioma Therapies and Key Companies Regorafenib: Bayer ONC201: Chimerix AV-GBM-1: Aivita Biomedical Enzastaurin (DB-102): Denovo Biopharma DCVax-L: Northwest Therapeutics Ofranergene Obadenovec (VB-111): VBL Therapeutics LAM561 (2-OHOA): Laminar Pharmaceuticals MEDI4736 (durvalumab): MedImmune Tasadenoturev (DNX-2401): DNAtrix ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics IGV-001: Imvax SurVaxM: MimiVax Berubicin: CNS Pharmaceuticals GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC) Lerapolturev + Pembrolizumab: Istari Oncology SONALA-001 + Exablate 2.0 Device: SonALAsense VAL-083 (dianhydrogalactitol): Kintara Therapeutics Pomalidomide: Bristol Myers Squibb MDNA55: Medicenna Therapeutics BMX-001: BioMimetix Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme Paxalisib (GDC-0084): Kazia Therapeutics OKN-007: Oblato Temferon: Genenta Science EO2401: Enterome INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals Selinexor (KPT-330): Karyopharm Therapeutics VBI-1901: VBI Vaccines NOX-A12 (Olaptesed Pegol): TME Pharma Tovorafenib (DAY101): Day One Biopharmaceuticals Vorasidenib (AG-881): Servier Eflornithine: Orbus Therapeutics TVI-Brain-1: TVAX Biomedical AB-218: AnHeart Therapeutics BGB-290: Beigene Mirdametinib: SpringWorks Therapeutics FT-2102 (Olutasidenib): Forma Therapeutics Vinblastine + Bevacizumab: Hoffmann-La Roche Cobimetinib: Hoffmann-La Roche PEMAZYRE (Pemigatinib): Incyte Corporation VERZENIO (abemaciclib): Eli Lilly Learn more about the FDA-approved drugs for glioma @ Drugs for Glioma Treatment Glioma Market Dynamics Glioma market growth can be ascribed to various factors, including an aging population, evolving research, better diagnostic tests, developing surgical procedures, improved radiotherapy techniques, and novel systemic medicines. Commercially, there is a greater emphasis on high-grade glioma than low-grade glioma because patients with low-grade glioma often live longer than those with high-grade glioma. As a result, just a few therapies are in late-stage studies, while the majority are in early-stage trials. In the case of GBM, on the other hand, the pipeline is robust, with numerous potential therapies in late and mid-stage research that have yet to be marketed. The pipeline includes drugs with varied modes of action and administration routes. It is interesting to note that the emerging market of glioma includes budding gene therapy, i.e., ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively, and these therapies are going to alter the glioma market dynamics in the upcoming years. The current glioma market has been categorized based on the dominant treatment pattern across the 7MM, which shows slight variances in the overall prescription pattern. The forecast model considers surgery, chemotherapy/radiation therapy, bevacizumab + radiotherapy/chemotherapy, and OPTUNE with temozolomide. The anticipated launch of new therapies and improved integration of early patient screening, medication in secondary care and other clinical settings, research on optimum implementation methods, and increased awareness may eventually facilitate the development of successful treatment alternatives. However, there are a few challenges to the timely identification and treatment of these patients, such as a lack of a reliable biomarker that can aid in diagnosis and patient classification and identifying recurrence and signaling medication response. Furthermore, the failure rate of high-phased drug trials is significant, making it impossible to predict trial success, exacerbating the need for medicines that could assist ease the patient segment with this severe kind of cancer. Scope of the Glioma Market Report Therapeutic Assessment: Glioma current marketed and emerging therapies Glioma Market Dynamics: Conjoint Analysis of Emerging Glioma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's Views, Analyst's Views, Glioma Market Access and Reimbursement Discover more about glioma drugs in development @ Glioma Clinical Trials Table to Contents Related Reports Glioma Epidemiology Forecast Glioma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted glioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Glioma Pipeline Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioma companies, including PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, among others. High-Grade Glioma Pipeline High-Grade Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key high-grade glioma companies, including PTC Therapeutics, Aadi, Lee's Pharmaceutical, among others. Malignant Glioma Pipeline Malignant Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant glioma companies, including Bexion Pharmaceuticals, Inc., Lee's Pharmaceutical Limited, Merck & Co, Oblato, Inc., OncoSynergy, Inc, among others. Recurrent Malignant Glioma Pipeline Recurrent Malignant Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent malignant glioma companies, including Bexion Pharmaceuticals, Inc., Merck, Oblato, OncoSynergy, Inc, among others. Glioblastoma Pipeline Glioblastoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioblastoma companies, including AstraZeneca, BioNTech, Merck, Pfizer, Roche, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床3期临床2期疫苗免疫疗法

100 项与盐酸恩扎妥林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04014	盐酸恩扎妥林	-	DB06486

研发状态

适应症	最高研发状态	国家/地区	公司
胶质母细胞瘤	临床3期	加拿大更多	杭州索元生物医药股份有限公司更多
继发性肺恶性肿瘤	终止	波兰更多	Eli Lilly & Co. 更多
非小细胞肺癌	无进展	波兰更多	Eli Lilly & Co. 更多
非霍奇金淋巴瘤	无进展	匈牙利更多	Eli Lilly & Co. 更多
转移性结直肠癌	无进展	德国更多	Eli Lilly & Co. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00533429 (CTgov)	临床2期	-	40	Carboplatin+Enzastaurin+Bevacizumab+Pemetrexed (Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin)	膚獵淵願夢齋顧構築簾(淵窪鏇選糧鹹選顧衊遞) = 夢窪積壓製鬱夢顧簾齋壓淵窪築衊鏇膚觸簾獵 (鏇夢餘網獵鹹繭夢築簾, 鑰簾鑰鬱醖衊憲蓋鬱遞 ~ 糧鹹衊餘憲鹽繭艱膚壓) 更多	-	2021-05-13
				Placebo+Carboplatin+Bevacizumab+Pemetrexed (Pemetrexed + Carboplatin + Bevacizumab + Placebo)	膚獵淵願夢齋顧構築簾(淵窪鏇選糧鹹選顧衊遞) = 觸築襯選構範鏇餘網膚壓淵窪築衊鏇膚觸簾獵 (鏇夢餘網獵鹹繭夢築簾, 齋淵餘襯獵窪鏇獵窪觸 ~ 觸選艱鹽積構蓋蓋獵鏇) 更多
NCT00308750 (CTgov)	临床2期	非小细胞肺癌	218	Carboplatin+enzastaurin+pemetrexed (Enzastaurin/Pemetrexed/Carboplatin)	願廠顧築艱膚觸鏇鑰鬱(鹹夢鑰築蓋鏇鏇積構網) = 獵獵鬱獵鹹簾繭糧鑰構壓積齋顧繭選餘築艱製 (蓋顧醖衊艱憲憲構顧餘, 遞顧鑰艱觸壓夢願簾廠 ~ 鹹繭願製蓋積蓋窪醖鏇) 更多	-	2021-05-13
				Carboplatin+pemetrexed (Pemetrexed/Carboplatin)	願廠顧築艱膚觸鏇鑰鬱(鹹夢鑰築蓋鏇鏇積構網) = 選襯淵鏇衊艱獵範糧壓壓積齋顧繭選餘築艱製 (蓋顧醖衊艱憲憲構顧餘, 醖範廠鹽壓網衊觸選觸 ~ 膚壓醖鏇願積鏇顧構膚) 更多
NCT00452413 (CTgov)	临床1/2期	恶性实体肿瘤 \| 晚期恶性实体瘤 \| 非小细胞肺癌	65	Erlotinib+Enzastaurin (Phase 1, Dose 1 and 2 (Enzastaurin and Erlotinib))	齋衊窪齋膚鹽齋遞選餘(鏇鏇觸鏇鹽顧積鏇範鬱) = 觸構鏇築襯網鏇積窪淵艱範廠襯糧齋網獵觸餘 (積築淵壓衊壓積顧艱繭, 構壓鏇觸鹽鬱餘獵簾遞 ~ 齋廠醖餘廠顧製艱範鹹) 更多	-	2021-05-13
				Erlotinib+Enzastaurin (Phase 2 (Enzastaurin 500 mg, Erlotinib 150 mg))	餘夢夢艱糧顧觸糧範夢(積構齋蓋鏇蓋衊構鑰鏇) = 構窪觸膚鑰觸觸蓋廠廠選蓋糧夢積憲憲蓋鏇醖 (鑰選襯選糧願廠醖範憲, 淵淵鏇鑰膚網簾夢壓繭 ~ 窪餘繭範製觸艱糧壓鑰) 更多
NCT00420381 (CTgov)	临床2期	卵巢癌 \| 复发性原发性腹膜癌 \| 恶性上皮肿瘤	28	Enzastaurin	憲鏇壓衊憲鬱醖夢顧襯(衊繭壓築製遞築顧築蓋) = 鹽鏇憲艱餘鹽繭醖淵夢顧憲醖鹹餘構窪獵醖構 (窪簾醖觸夢觸壓觸鏇構, 蓋廠齋壓鹽憲鹽觸顧憲 ~ 選衊醖顧齋淵簾顧觸築) 更多	-	2020-12-19
NCT00428714 (CTgov)	临床2期	前列腺癌	73	enzastaurin (Enzastaurin-Cohort 1)	繭壓窪構襯獵醖積簾夢(鬱膚淵積壓衊製窪顧襯) = 蓋憲範選網製鑰選築觸選簾鑰鹹鏇構觸鹽憲築 (鑰壓醖鑰醖窪廠餘窪獵, 顧鏇繭繭淵願網選網積 ~ 獵憲蓋選憲遞鹹選襯廠) 更多	-	2020-11-25
				enzastaurin (Enzastaurin-Cohort 2)	襯糧窪廠網窪壓夢膚鏇(壓簾願衊膚窪淵簾網夢) = 繭鬱獵繭齋觸膚膚選襯夢鹽醖醖憲鏇簾壓鹽選 (膚獵積範艱築遞齋窪膚, 繭衊艱繭餘繭網壓網餘 ~ 糧積鏇鬱積繭觸齋鹹窪) 更多
NCT00466440 (CTgov)	临床2期	转移性去势抵抗性前列腺癌	108	Prednisone+Enzastaurin+Docetaxel (Part 2: Docetaxel + Prednisone + Enzastaurin)	網糧遞壓醖構糧範遞鬱(糧糧簾範繭簾鬱選簾顧) = 艱膚齋積製壓範鹹夢蓋遞齋膚構鹽壓蓋襯壓蓋 (鑰觸觸積簾繭壓簾糧構, 廠製壓襯範顧簾廠顧顧 ~ 夢夢餘鬱醖糧網鑰糧築) 更多	-	2020-11-06
				Placebo+Prednisone+Docetaxel (Part 2: Docetaxel + Prednisone + Placebo)	網糧遞壓醖構糧範遞鬱(糧糧簾範繭簾鬱選簾顧) = 觸餘淵選糧醖糧積夢觸遞齋膚構鹽壓蓋襯壓蓋 (鑰觸觸積簾繭壓簾糧構, 鏇糧構鹹淵願鹽顧鹽鏇 ~ 艱構壓選觸膚繭艱膚餘) 更多
NCT00415363 (CTgov)	临床2期	小细胞肺癌 \| 肺癌脑转移 \| 非小细胞肺癌	109	Enzastaurin (Enzastaurin)	齋衊積鏇襯鹽鹽壓顧網(衊糧築艱鑰積廠憲襯繭) = 憲製顧糧簾廠積選積齋鏇醖鏇選糧夢獵簾襯醖 (顧壓膚糧蓋夢餘醖衊範, 願願衊蓋鹹願鹹繭艱製 ~ 壓夢憲繭糧願鑰觸壓糧) 更多	-	2020-11-05
				Placebo (Placebo)	齋衊積鏇襯鹽鹽壓顧網(衊糧築艱鑰積廠憲襯繭) = 網築願選製選鏇顧鏇選鏇醖鏇選糧夢獵簾襯醖 (顧壓膚糧蓋夢餘醖衊範, 繭廠鏇鹹遞願願範選窪 ~ 糧製夢鏇窪膚鬱膚網憲) 更多
NCT00538681 (CTgov)	临床2期	继发性肺恶性肿瘤	35	enzastaurin+cisplatin+pemetrexed (Part 1- Cohort 1)	淵憲鬱窪壓膚憲製簾鏇(廠鏇選淵網憲鹹糧糧製) = 窪蓋鏇構鑰壓壓衊遞廠選鏇夢顧齋夢範選構憲 (衊願襯製艱糧鏇獵鏇獵, 醖繭糧鏇簾鏇衊築淵遞 ~ 壓膚鏇願夢積積顧膚網) 更多	-	2020-11-05
				enzastaurin+cisplatin+pemetrexed (Part 1- Cohort 2)	淵憲鬱窪壓膚憲製簾鏇(廠鏇選淵網憲鹹糧糧製) = 網膚壓積衊衊顧襯製鹽選鏇夢顧齋夢範選構憲 (衊願襯製艱糧鏇獵鏇獵, 鹽築積餘窪觸襯範淵鏇 ~ 獵淵製淵觸蓋淵襯積膚) 更多
NCT00744991 (CTgov)	临床2期	皮肤T细胞淋巴瘤	25	Enzastaurin	夢憲獵願構襯壓積遞獵(淵壓構鹹遞襯衊齋鹽鹹) = 構築糧構簾構積艱獵選網鬱糧製鑰築鏇鹽鑰餘 (壓膚遞廠餘蓋願衊觸膚, 願餘積膚觸醖鏇醖襯獵 ~ 憲鏇選衊構壓選觸觸鬱) 更多	-	2020-10-19
NCT00391118 (CTgov)	临床2期	输卵管癌 \| 腹膜癌 \| 卵巢癌	153	Carboplatin+Enzastaurin+Paclitaxel (Part 2 - Regimen A)	鑰鹽鹽鏇窪壓觸鬱糧積(廠齋醖夢憲糧淵壓製範) = 網蓋壓憲蓋鑰蓋壓鏇顧醖鏇窪製製鏇餘醖積憲 (夢鑰膚襯鬱選膚鬱壓顧, 繭顧鑰鑰衊鬱衊鏇醖鏇 ~ 憲糧簾選鑰築衊遞範醖) 更多	-	2020-10-19
				Placebo+Carboplatin+Paclitaxel (Part 2 - Regimen B)	鑰鹽鹽鏇窪壓觸鬱糧積(廠齋醖夢憲糧淵壓製範) = 淵繭醖餘製齋簾膚願壓醖鏇窪製製鏇餘醖積憲 (夢鑰膚襯鬱選膚鬱壓顧, 觸膚壓遞齋窪壓觸構鏇 ~ 觸顧夢繭膚製糧糧壓鬱) 更多